source
- FDA launches Rare Disease Framework to embed patient input early in drug developmentFDA's Center for Biologics Research and Evaluation (CBER) director Karim Mikhail announced a new Rare Disease Framework Initiative aimed at moving patient perspectives from an optional, late‑stage…
- Third Rock Ventures commits up to $2.16 billion to AI-driven Chinese biotech Funnel BiosciencesThird Rock Ventures disclosed a partnership with Chinese biotech Funnel Biosciences, committing up to $2.16 billion to support its AI-driven biologics platform. The agreement includes a research c…